Karvezide, Avalide and Avapro HCT.[edit] References^ avapro off patent EJ, Hunsicker LG, Clarke WR, Berl T, Pohl MA, Lewis JB, avapro off patent E, Atkins RC, Rohde R, Raz I; Collaborative Study Group. (2001). "Renoprotective effect of the angiotensin-receptor antagonist irbesartan in patients with nephropathy due to type 2 diabetes.". N Engl avapro off patent Med 345.

OralIrbesartan (INN) (pronounced /?rb??s?rt?n/) is an angiotensin II receptor antagonists, irbesartan is indicated for the reduction of renal disease progression in patients with nephropathy due to type 2 diabetes.". avapro off patent Engl J Med 345 avapro off patent 851-60. PMID 11565517.^ Rossi S, editor. Australian Medicines Handbook; 2006. ISBN 0-9757919-2-3 IrbesartanFrom Wikipedia, the free encyclopedia(Redirected from Avapro)Jump to: navigation, searchIrbesartanSystematic (IUPAC) name2-butyl-3-[p-(o-1H-tetrazol-5-ylphenyl)benzyl]-1,3-diazaspiro[4.4]non-1-en-4-oneIdentifiersCAS number 138402-11-6ATC code C09CA04PubChem 3749DrugBank APRD00413Chemical dataFormula C25H28N6OMol. mass avapro off patent avapro off patent & PubChemPharmacokinetic dataBioavailability 60–80%Metabolism Hepatic (CYP2C9)Half life 11–15 hoursExcretion Renal 20%, avapro off patent 65%Therapeutic considerationsLicence data EU, USPregnancy cat. D (Au)Legal status S4 (Au), POM (UK), ?-only avapro off patent OralIrbesartan (INN) (pronounced /?rb??s?rt?n/) is an angiotensin II receptor antagonists.

(now part of sanofi-aventis). It is jointly marketed by sanofi-aventis and Bristol-Myers Squibb.